Schweitzer Fachinformationen
Wenn es um professionelles Wissen geht, ist Schweitzer Fachinformationen wegweisend. Kunden aus Recht und Beratung sowie Unternehmen, öffentliche Verwaltungen und Bibliotheken erhalten komplette Lösungen zum Beschaffen, Verwalten und Nutzen von digitalen und gedruckten Medien.
Preface xi
1 Brain Function, Physiology and the Blood-Brain Barrier 1
1.1 Introduction - An Overview of Brain Structure and Function 1
1.1.1 The Forebrain 1
1.1.2 The Midbrain 4
1.1.3 The Hindbrain 4
1.2 The Cell Types of the Brain 7
1.2.1 Neurons 7
1.2.2 Glial Cells 11
1.3 The Blood-Brain Barrier 19
References 21
2 Role of Metal Ions in Brain Function, Metal Transport, Storage and Homoeostasis 23
2.1 Introduction - The Importance of Metal Ions in Brain Function 23
2.2 Sodium, Potassium and Calcium Channels and Pumps 24
2.3 Calcium and Signal Transduction 30
2.4 Zinc, Copper and Iron 37
2.5 Zinc 37
2.6 Copper 41
2.7 Iron 42
References 48
3 Immune System and Neuroinflammation 51
3.1 General Introduction 51
3.1.1 Innate Immune Response and Neuroinflammation 51
3.1.2 Adaptive Immunity and Neuroinflammation 58
3.1.3 Adaptive Immunity and Neuroinflammation 59
3.1.4 Other Factors Contributing to Neuroinflammation 60
3.1.5 Anti-inflammatory Systems to Regulate Microglia Activation 60
3.2 Apoptosis 63
3.2.1 Iron Metabolic Regulators and Effectors during Inflammation 68
References 72
4 Oxidative Stress in Neurodegenerative Diseases 75
4.1 Introduction - The Oxygen Paradox 75
4.2 Reactive Oxygen Species 76
4.3 Reactive Nitrogen Species 79
4.4 Cellular Defence Mechanisms against Oxidative Stress 82
4.5 ROS, RNS and Cellular Signalling 87
4.6 ROS, RNS and Oxidative Damage 91
4.7 Epigenetics 97
4.7.1 Histone Modifications 100
4.8 Misfolded Protein Aggregates in Neurodegenerative Diseases 101
4.9 The Amyloid State - Structure, Nucleation and Aggregation 102
References 107
5 Ageing and Mild Cognitive Impairment (MCI) 111
5.1 Introduction 111
5.1.1 Gene Involvement and Epigenetics 112
5.1.2 DNA Methylation 112
5.1.3 Histone Post-translational Modifications 113
5.2 Prevalence of MCI 114
5.2.1 MCI Presentation 114
5.3 Brain Regions Involved 115
5.3.1 Neurochemical Observations 116
5.3.2 Factors Involved in the Ageing Process 117
5.3.3 Mitochondria and the Ageing Process 117
5.3.4 Free Radical Theory of Ageing 118
5.3.5 Iron, Copper and Zinc in Ageing 119
5.3.6 Risk Factors for Cognitive Decline 121
5.3.7 APOe4 Isoforms and MCI 122
5.3.8 Ageing and Immunity 122
5.4 Proteostasis 126
5.5 Conclusion 127
References 128
6 Parkinson's Disease 131
6.1 Risk Factors for PD 131
6.2 Genetics of PD 134
6.3 SNCA 135
6.4 LRRK2 135
6.5 Parkin 135
6.6 DJ-1 135
6.7 PINK1: PTEN-Induced Kinase 136
6.8 Epigenetics 136
6.9 miRNA 136
6.10 Proteins Involved in PD 137
6.11 Synucleins 137
6.12 LRRK2 or PARK 8 142
6.13 PINK1 or PTEN-Induced Putative Kinase 1, PARK6 143
6.14 Parkin, PARK2 144
6.15 Synphilin-1 146
6.16 UCHL 1, Park 5 147
6.17 DJ-1, PARK 7 147
6.18 Metal Involvement in Parkinson's Disease 148
6.18.1 Iron 148
6.18.2 Zinc 153
6.18.3 Copper 154
6.19 Neurotransmitters Involved in PD 154
6.20 Mitochondrial Dysfunction 156
6.21 PD and Inflammation 156
6.22 Receptors Involved in the Inflammatory Response 159
6.22.1 Toll-Like Receptors 159
6.22.2 Glucocorticoid Receptor, GR 159
6.22.3 CD200/CD200R 160
6.22.4 Vitamin D Receptor (VDR) 160
6.22.5 Peroxisome Proliferators-Activated Receptors 161
6.23 Oxidative Stress and PD 161
References 163
7 Alzheimer's Disease 169
7.1 Introduction 169
7.2 Epidemiology and Risk Factors for AD 171
7.3 Genetics of AD 173
7.3.1 Epigenetics 174
7.4 Proteins Involved in Alzheimer's Disease 175
7.5 Metal Involvement in Alzheimer's Disease 179
7.6 Zinc Homoeostasis in AD 181
7.7 Copper Homoeostasis in AD 181
7.8 Iron Homoeostasis in AD 183
7.9 Neurotransmitters Involved in AD 185
7.9.1 Acetyl choline 185
7.9.2 Glutamate 187
7.10 Mitochondrial Function in Alzheimer's Disease 189
7.11 Neuroinflammation and AD 191
7.12 Oxidative Stress 191
References 195
8 Huntington's Disease and Polyglutamine Expansion Neurodegenerative Diseases 203
8.1 Introduction 203
8.2 An Overview of Trinucleotide Expansion Diseases 204
8.3 Poly-Q Diseases 204
8.4 Poly-Q Protein Aggregation and Poly-Q Disease Pathogenesis 208
8.5 Huntington's Disease 211
8.6 Other Poly-Q Disease Proteins 215
8.7 Spinocerebellar Ataxias 218
References 221
9 Friedreich's Ataxia and Diseases Associated with Expansion of Non-Coding Triplets 227
9.1 Incidence and Pathophysiology of Friedreich's Ataxia 227
9.2 Molecular Basis of the Disease: Triplet Repeat Expansions 228
9.3 Molecular Basis of the Disease: Frataxin and Its Role in Iron Metabolism 230
9.4 Other Diseases Associated with Expansion of Non-Coding Triplets 233
References 236
10 Creutzfeldt-Jakob and Other Prion Diseases 239
10.1 Introduction 239
10.2 A Brief History of Prion Diseases 240
10.3 Structural Aspects of the Cellular Form of PrPC 241
10.4 'Prion' or 'Protein-Only' Hypothesis - Conformation-Based Prion Inheritance 244
10.5 Models of PsPC to PsPSc Conversion 246
10.6 Formation of Prion Aggregates 248
10.7 Pathways of Prion Pathogenesis 253
References 256
11 Amyotrophic Lateral Sclerosis 261
11.1 Introduction 261
11.2 Major Genes Involved in ALS 262
11.3 Superoxide Dismutase and ALS 265
11.4 Contributors to Disease Mechanisms in ALS 269
11.5 Excitotoxicity and Decreased Glutamate Uptake by Astroglia 269
11.6 Endoplasmic Reticulum Stress 270
11.7 Inhibition of the Proteasome 270
11.8 Mitochondrial Damage 271
11.9 Aberrant Secretion of Mutant SOD1 271
11.10 Extracellular Superoxide Generation 271
11.11 Axonal Disorganization and Disrupted Transport 272
11.12 Microhaemorrhages of Spinal Capillaries 272
11.13 Glial Cells in ALS 273
11.14 ALS and Apoptosis 273
11.15 Prion-Like Phenomena in ALS 274
11.16 Conclusions 276
References 276
12 Alcoholic Brain Damage 283
12.1 General Introduction 283
12.2 Anatomy of Alcohol-Induced Damage 285
12.3 Genetics of Alcohol-Induced Brain Damage 286
12.3.1 Epigenetics 286
12.3.2 MicroRNAs 287
12.3.3 Genetics 288
12.4 Factors Associated with Alcohol Brain Damage 291
12.5 Factors Involved in Alcohol-Induced Brain Damage 292
12.5.1 Neuropeptides 292
12.5.2 Neurotransmitters 293
12.5.3 Acetaldehyde 294
12.5.4 Signalling Pathways 295
12.5.5 Neuroinflammation and Alcohol 296
12.5.6 Astrocytes and Alcohol 297
12.5.7 Microglia and Alcohol 300
12.5.8 NF-kB 301
12.5.9 Toll-Like Receptors 302
12.5.10 Oligodendrocytes and Alcohol 303
12.5.11 Alcohol and Mitochondria 303
12.5.12 Alcoholic Brain Damage and Oxidative Stress 304
References 305
13 Other Neurological Diseases 309
13.1 Introduction 309
13.2 Wilson's and Menkes Diseases 309
13.3 Neurodegeneration with Brain Iron Accumulation 316
13.4 Aceruloplasminaemia 316
13.5 Neuroferritinopathy 318
13.6 Other Neurodegenerative Disorders with Brain Iron Accumulation 320
13.7 Multiple Sclerosis 323
13.8 HIV-Associated Neurocognitive Disorder 329
References 332
14 Therapeutic Strategies to Combat the Onset and Progression of Neurological Diseases 337
14.1 Introduction 337
14.2 Chelation of Excessive Metal Ions 338
14.2.1 Chelation in Parkinson's Disease 341
14.2.2 Chelation Therapy in AD 341
14.2.3 Chelation in Friedreich Ataxia 343
14.3 Ageing and Cognitive Decline 344
14.3.1 Saturated/Unsaturated Fat Intake 344
14.3.2 Berries 345
14.3.3 Creatine Supplementation 346
14.3.4 Sirtuins 347
14.3.5 Immunity 347
14.3.6 Mitochondria Mutations 348
14.4 Parkinson's Disease 348
14.4.1 Nutraceutical 349
14.4.2 NASIs and COX2 Inhibitors 351
14.4.3 Physical Exercise 351
14.4.4 Dopamine Agonists 352
14.4.5 Monoamine Oxidase Inhibitors 354
14.4.6 L-DOPA 355
14.4.7 Mitochondria and PD 356
14.4.8 Sirtuins 356
14.4.9 Creatine 357
14.4.10 CoQ10 358
14.4.11 Surgical Treatment for PD 358
14.5 Alzheimer's Disease 359
14.5.1 Epigenetic Modifications 359
14.5.2 Sirtuins 359
14.5.3 Tau Kinase Inhibitors 359
14.5.4 Neurotransmitters 360
14.5.5 Anti-inflammatory Drugs 360
14.5.6 Strategies to Remove Ab 360
14.5.7 Ab Immunotherapy 363
14.6 Huntington's Disease and Other Poly-Q Diseases 364
14.7 Friedreich's Ataxia and Other Non-Coding Nucleotide Repeat Diseases 367
14.8 Creutzfeld-Jakob and Other Prion Diseases 370
14.9 Amyotrophic Lateral Sclerosis 372
14.10 Alcohol Abuse 373
14.11 Other Neurological Diseases 378
14.11.1 Wilson's and Menkes Diseases 378
14.11.2 Neurodegeneration with Brain Iron Accumulation 379
14.12 Multiple Sclerosis 381
14.13 HIV-Associated Neurocognitive Disorder 386
References 387
15 Concluding Remarks 395
15.1 New Innovative Therapeutics 400
15.1.1 Stem Cells 402
15.2 Biochemical Biomarkers of Neurodegenerative Diseases 404
15.2.1 Parkinson's Disease 404
15.2.2 Alzheimer's Disease 404
15.2.3 Alcohol Brain Damage 405
15.2.4 Epilogue 405
References 406
Index
2
Role of Metal Ions in Brain Function, Metal Transport, Storage and Homoeostasis
Organic molecules, based on the elements C, H, N and O, such as amino acids, carbohydrates, lipids and their constituent fatty acids, purines and pyrimidine bases and the polymers made out of them, proteins, polysaccharides and the nucleic acids RNA and DNA, are extremely important for living organisms. However, in order to fulfil a series of important functions such as energy production, nerve transmission, muscle contraction and oxygen transport, metal ions are also absolutely essential. They include the alkali and alkaline earth metals potassium, sodium, calcium and magnesium together with the transition metals cobalt, copper, iron, manganese, zinc and a few others. Some of these metal ions are particularly important for brain function, and the term metalloneurochemistry has been proposed to describe the study of metal ions in the brain and the nervous system at the molecular level (Burdette and Lippard, 2003).
Na+ and K+ play a crucial role in the transmission of nervous impulses. The opening and closing of ion channels generates electrochemical gradients across the plasma membranes of neurons. As we will see shortly, nerve impulses are propagated by action potentials which result from a transient increase in the permeability of the membrane to Na+ rapidly followed by a transient increase in its permeability to K+. The determination of high-resolution X-ray structures of the K+ ion channel has allowed us to understand how it selectively filters completely dehydrated K+ ions, but not the smaller Na+ ions.
Within most cells, including nerve cells, fluxes of Ca2+ ions play an important role in signal transduction. Ca2+ channels mediate Ca2+ influx into neurons in response to membrane depolarization, mediating a wide range of intracellular processes such as activation of calcium-dependent enzymes, gene transcription and neurotransmitter exocytosis/secretion. Their activity is an essential requirement for the coupling of electric signals in the neuronal plasma membrane to physiological events within the cells.
Another metal ion that has been implicated considerably in brain function is Zn2+. In mammalian brain, the vast majority of zinc is tightly bound within zinc metalloproteins in neurons and glial cells as a structural or as a catalytic co-factor. However, approximately 10% of the total zinc, probably ionic zinc, is less tightly bound and is mainly localized within the synaptic vesicles of the forebrain, in a subset of glutamatergic axon terminals, as we will see shortly. When hippocampal fibres are stimulated, large amounts of Zn are co-released with glutamate and it could be that this synaptic pool of Zn functions as a neuromodulator.
Redox metal ions also play an important role in brain function. Metalloenzymes containing these metals play extremely important roles in a number of key metabolic pathways within nervous tissues, They are, for example, involved in neurotransmitter synthesis (the Fe enzyme, tyrosine hydroxylase in the formation of DOPA from tyrosine and the Cu enzyme dopamine ß-hydroxylase which transforms dopamine to nor-adrenaline) and in neuroprotection (the Cu/Zn superoxide dismutase in cytosol and the Mn superoxide dismutase in mitochondria). However, as we will see in later chapters, the presence of any of these redox-active metals in excess within localized regions of the central nervous system (CNS) frequently spells disaster, with associated neurodegeneration.
Nerve impulses consist of a wave of transient membrane depolarization/re-polarization which traverses the nerve cell and is designated an action potential. In their Nobel Prize-winning studies1 to uncover the ionic mechanism of action potentials, Alan Hodgkin and Andrew Huxley carried out experiments on the giant axon of the squid (Hodgkin and Huxley, 1952). The large diameter of the axon (up to 1 mm, typically 0.5 mm) allowed them to insert voltage clamp electrodes inside the lumen of the axon and measure the action potential (Figure 2.1a). The depolarization is caused by the transient opening of Na+ channels resulting in an influx of 3.7 pmol/cm2 of Na+ (Figure 2.1b). This is offset by a more prolonged influx of 4.3 pmol/cm2 of K+ which begins a fraction of a millisecond later. The outcome is that in the first ~0.5 ms, the membrane potential increases from the resting potential of around -60 mV to about +30 mV. The Na+ channels now become refractory and no more Na+ enters the cell, while K+ channels remain open, causing a rapid repolarization, which allows the membrane potential to overshoot the resting potential (hyperpolarization) before the K+ channels also inactivate, allowing the membrane to recover to its initial value. The voltage-gated Na+ and K+ ion channels across the axonal membranes create the action potentials (essentially electrochemical gradients) which allow information transfer and also regulate cellular function.
Figure 2.1 The time course of an action potential. (a) The axon membrane undergoes rapid depolarization followed by a nearly as rapid hyperpolarization and then a slow recovery to its resting potential. (b) The depolarization is caused by a transient increase in Na+ permeability (conductance), whereas the hyperpolarization results from a more prolonged increase in K+ permeability that begins a fraction of a millisecond later. [From Voet, D. and Voet, J.G. (2011) Biochemistry, 4th edn. © John Wiley & Sons. This material is reproduced with permission of John Wiley & Sons, Inc.]
The axons of larger vertebrates are enveloped in a myelin sheath which electrically isolates the axon from the extracellular medium. The myelin sheath surrounding CNS axons is the plasma membrane of an oligodendrocyte [in the peripheral nervous system (PNS), this role is performed by Schwann cells], which, as it spirally grows around the axon, extrudes its cytoplasm from between the layers. The resulting double bilayer, which makes 10-150 turns about the axon, is an excellent insulator on account of its high lipid content. Nerve impulses in myelinated nerves propagate with velocities up to 100 m/s, as much as 100 times faster than in unmyelinated nerves. The myelin sheaths are interrupted every millimetre or so along the axon by unmyelinated gaps, known as the nodes of Ranvier (Figure 2.2) where the axon contacts the extracellular medium. Whereas the unmyelinated nerves have a uniform distribution of voltage-gated Na+ channels of ~20 channels/µm2, the Na+ channels of myelinated axons occur only at the nodes of Ranvier, concentrated at ~104 channels/µm2. The action potential hops between these nodes, a process known as saltatory conduction (Latin saltare, jump). Nerve impulse transmission between nodes occurs by passive conduction of an ionic current, a process inherently much more rapid than continuous propagation. The nodes also act as amplification stations maintaining the intensity of the electrical impulse as it travels down the axon. As we discuss in a later chapter, multiple sclerosis is an autoimmune disease which demyelinates nerve fibres in the brain and the spinal cord.
Figure 2.2 (a) An electron micrograph of myelinated nerve fibres in cross section. The myelin sheath surrounding the axon is the plasma membrane of an oligodendrocyte or a Schwann cell, which extrudes its cytoplasm from between the layers as it grows spirally around the axon. The resulting bilayer, which makes between 10 and 150 turns about the axon, is a good conductor of electricity because of its high lipid content (about 80%). (b) A schematic diagram of a myelinated axon in longitudinal cross section. The axonal membrane is in contact with the external medium at the nodes of Ranvier. A depolarization generated by an action potential at one node hops down the myelinated axon (arrows) at the neighbouring node, where it induces a new action potential. This results in saltatory conduction. [From Voet, D. and Voet, J.G. (2011) Biochemistry, 4th edn. © John Wiley & Sons. This material is reproduced with permission of John Wiley & Sons, Inc.]
Transport across membranes is carried out by two classes of membrane proteins, channels and pumps. Channels allow ions to flow down a concentration gradient by a process known as passive transport or facilitated diffusion. Channels cannot remain open all the time and so they are usually gated, which simply means that, like regular garden gates, they usually remain shut and can only be opened either by the binding of a ligand (ligand-gated) or by changes in the membrane potential (voltage-gated). Ligand-gated channels, like the acetylcholine receptors in postsynaptic membranes, are opened by the binding of the neurotransmitter acetylcholine, whereas the voltage-gated sodium and potassium channels, which mediate the action potentials in neuronal axons described below, are opened by membrane depolarization.
In contrast, pumps use energy in the form of either ATP or light to drive the unfavourable uphill transport of ions or molecules against a concentration gradient; in other words, they are involved in active transport. There are two types of ATP-driven pumps, the so-called P-type ATPases and...
Dateiformat: ePUBKopierschutz: Adobe-DRM (Digital Rights Management)
Systemvoraussetzungen:
Das Dateiformat ePUB ist sehr gut für Romane und Sachbücher geeignet – also für „fließenden” Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein „harter” Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.Bitte beachten Sie: Wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!
Weitere Informationen finden Sie in unserer E-Book Hilfe.